Discussing the landscape of deal structures in the biotech industry, experts will provide their experience in deal-making and asset-licensing. What are the different deal structures? Has there been any innovative and less conventional deal structure types in the past few years for licensing early-stage assets to big pharma? How do deal structures vary based on the area of technology or therapeutic indication, and what factors influence their adoption? What considerations should biotech or TTOs take into account when exploring deal structures with pharma? How will Pharma select potential assets in the future? What are the key points of a successful deal? What best practices can we learn from the recent years and what advice can the experts offer to the newcomers in the sector?

Moderator: Chris Shelley, Partner – IP, IT & Commercial, Penningtons Manches Cooper LLP